You can still follow Chris Behrenbruch on twitter. Judge for yourself, whether this is of a quality that befits representation on ASX listed Factor Therapeutics and Telix Pharam.
That 2015 story was one of a number he wrote, at the time. The story came post the Yale arrangement that Novogan already had in place.
The baby faced Dr Chris Behrenbruch v Yale.
You already know where I have my money.
NRT Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
